Takeda has announced that BRANCH-003the experimental dengue vaccine, managed to prevent 84% of dengue cases requiring hospitalization for dengue and 61% of symptomatic cases, with no significant safety concerns identified in the general population, including seropositive and seronegative individuals over a period of 4 and half a year (54 months) after vaccination.
This, according to a pivotal phase 3 clinical study called TIDES (Efficacy Study of Tetravalent Immunization against Dengue).
It should be remembered that dengue is the viral disease transmitted by a mosquito with the fastest spread and was included in the ranking of the 10 most important threats to global public health according to the WHO in 2019.
The dengue fever It is mainly transmitted by the Aedes aegypti mosquito and to a lesser extent by the Aedes albopictus.
Source: El heraldo
John Cameron is a journalist at The Nation View specializing in world news and current events, particularly in international politics and diplomacy. With expertise in international relations, he covers a range of topics including conflicts, politics and economic trends.